 |
 |
 |
||||||
 |
||||||||
 |
 |
 |
 |
|||||
 |
 |
 |
|
|||||
|
|
|
|
|
|
|
|
|
 |
 |
|
| Although
the sequences of many therapeutically relevant genes have been patented
as isolated or purified sequences, a major advantage of Sangamo’s
unique technology is that it regulates endogenous cellular genes and
is consequently independent of such patents. We have been granted
a U.S. patent that includes claims covering the activation or repression
of any endogenous gene in any cell type using zinc finger DNA-binding
proteins. |
||
|
|
|
 |
 |
|
 |
2006 Press Archive | |
|
2005 Press Archive | |
|
2004 Press Archive | |
|
2003 Press Archive | |
|
2002 Press Archive | |
|
2001 Press Archive | |
|
2000 Press Archive | |
|
|
|
Recent Press Releases